Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 25, 2009

TTY Biopharm to Produce to-BBB’s Brain Cancer Candidate

  • Dutch biotech company to-BBB is enlisting the help of Taiwanese drug formulation firm TTY Biopharm for the future manufacture of clinical-grade brain-targeting doxorubicin liposome candidate for the treatment of brain cancer. 

    TTY operates an EMEA-approved facility in ChangLi and already manufactures and markets Lipo-Dox®, a pegylated liposomal doxorubicin, in the Taiwanese and Asian markets. The company’s core technologies include liposomal, microemulsion, and sustained-release oral and injectable formulations.

    To-BBB’s brain-targeting doxorubicin liposome candidate is currently in preclinical development. The lead product is based on the company’s G-Technology, which involves coating the liposomes with glutathione at the tips of the polyethylene glycol. to-BBB claims the technology improves the safe delivery of free drug to the brain. The G-Technology was originally developed at the Industrial Technology Research Institute in Taiwan. 

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »